ABVC BioPharma (ABVC) 10-Q/A 19 Mar 18 2017 Q3 Quarterly report (amended) Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jun. 30, 2017	Aug. 18, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	American BriVision (Holding) Corp
Entity Central Index Key	1,173,313
Amendment Flag	true
Amendment Description	Explanatory Note American BriVision (Holding) Corporation (together with its subsidiary, the “Company” sometimes referred to as “we”, “us” or “our”) is filing this Amendment No. 1 (this “Amendment No.1” or “Form 10-Q/A”) to its Quarterly Report on Form 10-Q for the period ended June 30, 2017, originally filed on August 21, 2017, (the “Original Form 10-Q”) to reflect the restatement of its consolidated financial statements for the period ended June 30, 2017, and related disclosures described below. The restatement of the Original Form 10-Q reflected in this Amendment No.1 corrects revenue, gross profit, net loss from operations, loss from continuing operations before income taxes, and net loss for the three and nine months ended June 30, 2017, additional paid-in capital and accumulated deficit as of June 30, 2017, and the disclosures of related party transaction (see Note 6) and earnings per share (see Note 9) for the three and nine months ended June 30, 2017. There is no impact or changes to the total assets, total liability and total stockholders’ equity as of June 30, 2017. For details of the changes, please refer to Note 2 of the consolidated financial statements. No other sections were affected, but for the convenience of the reader, this report on Form 10-Q Amendment No. 1 restates in its entirety, as amended, our Original Form 10-Q. This report on Form 10- Q Amendment No.1 is presented as of the filing date of the Original Form 10-Q and does not reflect events occurring subsequent to the date of filing of the Original Form 10-Q. Background of Restatements in Amendment No.1 The additional paid-in capital and accumulated deficit as of June 30, 2017 was erroneously stated as $10,586,464 and $(11,848,288), respectively, on the Original Form 10-Q. The Company restated the additional paid-in capital and accumulated deficit as of June 30, 2017 as $10,746,464 and $(12,008,288), respectively. The error as a result of related party under common control transactions caused $160,000 difference in both accounts. There is no impact on the ending balance of the total stockholders’ equity as of June 30, 2017. The Company also restated revenue, gross profit, net loss from operations, loss from continuing operations before income taxes, and net loss in its statements of operation for the three and nine months ended June 30, 2017 for the same reason. On the Notes 6 to Consolidated Financial Statements of the Original Form 10-Q, the Company recorded revenues of $160,000, of which $70,000 was attributable to a consulting service provided to a Company’s shareholder, LionGene Corporation and $90,000 was as a result of the co-development with related party, Rgene Corporation (see Note 5 and Note 6). The Company determined that the total amount of $160,000 should be recorded as additional paid-in capital since the Company, LionGene Corporation, and Rgene Corporation are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation, and should be treated as the correction of error as of June 30, 2017. On the Notes 9 to Consolidated Financial Statements of the Original Form 10-Q, the net loss in the disclosure of the earning per share for the three and nine months ended June 30, 2017 was erroneously reflected as $(127,879) and $(524,887), respectively. The earning-per-share on the Original Form 10-Q for the three and nine months ended June 30, 2017 was $(0.00060) and $(0.00247), respectively, which were recorded as $(0.00) and $(0.00). The Company corrected the net loss in the disclosure of the earning per share for the three and nine months ended June 30, 2017 to $(217,879) and $(684,887), respectively in order to align with the net loss and weight-average shares outstanding basic and diluted as reflected on the accompanying unaudited Condensed Consolidated Statements of Operations for the three and nine months ended June 30, 2017. The corrected earning per share was $(0.00102) and $(0.00323), respectively, which are shown as $(0.00) and $(0.00). The overall impact in the earning-per-share for the three and nine months ended June 30, 2017 is $(0.00042) and $(0.00076), respectively. Items Amended by the Amendment No.1 This Amendment reflects the results of the work described above and includes the restatement of our consolidated financial statements for the period ended June 30, 2017. For the convenience of the reader, this Amendment sets forth the Original Form 10-Q, as modified and superseded where necessary to reflect the restatement and other related adjustments, internal control matters, and as otherwise specifically indicated. Specifically, the following items included in the Original Form 10-Q are amended by this Amendment: - Part I, Item 1, Financial Statements - Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operation
Trading Symbol	MTOO
Current Fiscal Year End Date	--09-30
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		213,746,647

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Current assets
Cash	$ 8,053	$ 173,537
Total Current Assets	8,053	173,537
Deposit		3,815
Total Assets	8,053	177,352
Liabilities and Equity
Accounts Payable		18,370
Accrued expenses	103,130	38,100
Due to related party	953,000	6,500,000
Total Liabilities	1,056,130	6,556,470
Commitments and Contingencies
Stockholders' equity (deficit)
Common Stock 360,000,000 authorized at $0.001 par value; shares issued and outstanding 213,746,647 and 210,821,647 at June 30, 2017 and September 30, 2016	213,747	210,822
Additional paid-in capital	10,746,464	4,733,461
Accumulated deficit	(12,008,288)	(11,323,401)
Total equity (deficit)	(1,048,077)	(6,379,118)
Total liabilities and equity (deficit)	$ 8,053	$ 177,352

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Sep. 30, 2016
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, share authorized	360,000,000	360,000,000
Common stock, shares issued	213,746,647	210,821,647
Common stock, shares outstanding	213,746,647	210,821,647

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Income Statement [Abstract]
Revenues
Cost of sales				32
Gross profit/(loss)				(32)
Operating expenses
Selling, general and administrative expenses	169,427	289,098	562,930	349,486
Research and development expenses	17,500		67,848	10,000,000
Stock based compensation	2,552		5,928
Total operating expenses	189,479	289,098	636,706	10,349,486
Net loss from operations	(189,479)	(289,098)	(636,706)	(10,349,518)
Other income(expense)
Bank Interest Income	100	361	149	361
Gain on exchange differences		89		141
Interest Expense	(28,500)	(3,753)	(47,500)	(3,753)
Total Other income (expenses)	(28,400)	(3,303)	(47,351)	(3,251)
Loss from continuing operations before income taxes	(217,879)	(292,401)	(684,057)	(10,352,769)
Income taxes expenses		(836)	(830)	(836)
Net loss	$ (217,879)	$ (293,237)	$ (684,887)	$ (10,353,605)
Basic and Diluted loss per share
Basic and diluted loss per share	$ 0	$ 0	$ 0	$ (0.05)
Weighted average number of shares outstanding basic and diluted	213,746,647	208,779,424	212,203,790	208,779,424

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities
Net loss from continuing operations	$ (684,887)	$ (10,353,605)
Issuance of common stocks for compensation	5,928	897,521
Income taxes paid	(830)
Adjustments to reconcile net loss to net cash used by operating activities:
(Increase) decrease in deposit	3,815
(Increase) decrease in prepayment		3,815
Increase (decrease) in other payable		(300,000)
Increase (decrease) in due to related party	(647,000)	6,477,483
Increase (decrease) in accounts payable	(17,540)	11,446
Increase (decrease) in accrued expenses	65,030
Net cash used in operating activities	(1,275,484)	(3,263,340)
Cash flows from financing activities
Capital contribution from related parties under common control	160,000
(Decrease) increase in due to shareholder		(46,586)
Proceeds from short term loans		2,050,000
Borrowings from related party	950,000
Proceeds from subscription receivable		350,000
Net cash provided by financing activities	1,110,000	2,353,414
Effect of exchange rates of cash
Net decrease in cash	(165,484)	(909,926)
Cash, beginning of period	173,537	994,830
Cash, end of period	8,053	84,904
Non cash investing and financing activities
Prepayment		900,000
Supplemental disclosure of cash flow information
Interest paid
Income taxes paid

Organization and Description of

Organization and Description of Business	9 Months Ended
	Jun. 30, 2017
Organization and Description of Business [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	1. ORGANIZATION AND DESCRIPTION OF BUSINESS American BriVision (Holding) Corporation (the “Company” or “Holding entity”), a Nevada corporation, through the Company’s operating entity, American BriVision Corporation (“BriVision”), which was incorporated in July 2015 in the State of Delaware, engages in biotechnology and focuses on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions (such as Memorial Sloan Kettering Cancer Center (“MSKCC”) and MD Anderson Cancer Center), conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets. REVERSE MERGER On February 8, 2016, a Share Exchange Agreement (“Share Exchange Agreement”) was entered into by and among the Company, BriVision, Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People Republic of China (“Euro-Asia”), being the owners of record of 52,336,000 shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 52,936,583 shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 51,945,225 shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision. Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision became a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement. Because of the consummation of the Share Exchange, as of February 8, 2016, BriVision is now our wholly owned subsidiary and its shareholders own approximately 79.70% of our issued and outstanding common stock. Following the Share Exchange, we have abandoned our prior business plan and we are now pursuing BriVision’s historical businesses and proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company is to integrate research achievements from world-famous institutions, conduct clinical trials of translational medicine for Proof of Concept (“POC”), out-license to international pharmaceutical companies, and exploit global markets. Accounting Treatment of the Reverse Merger For financial reporting purposes, the Share Exchange represents a “reverse merger” rather than a business combination and BriVision is deemed the accounting acquirer in the transaction. The Share Exchange is being accounted for as a reverse-merger and recapitalization. BriVision is the acquirer for financial reporting purposes and the Company is the acquired company. Consequently, the assets and liabilities and the operations reflected in the historical financial statements prior to the Share Exchange will be those of BriVision and recorded at the historical cost basis of BriVision. In addition, the consolidated financial statements after completion of the Share Exchange will include the assets and liabilities of the Company and BriVision, and the historical operations of BriVision and operations of the Combined Company from the closing date of the Share Exchange.

Corrections to Previously Issue

Corrections to Previously Issued Consolidated Financial Statements	9 Months Ended
	Jun. 30, 2017
Corrections to Previously Issued Consolidated Financial Statements [Abstract]
CORRECTIONS TO PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS	2. CORRECTIONS TO PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS Restatement for the period ended June 30, 2016 The Company has filed an amendment to its Quarterly Report, originally filed on August 15, 2016, on Form 10-Q for the period ended June 30, 2016 on February 22, 2017. The Company discovered that there was a delay of accrual for the two payments in total of $10,000,000 as set forth in the Collaborative Agreement: 1) 3.5% of total payment related to the upfront payment shall be made upon the execution of the Collaborative Agreement; and 2) 6.5% of the total payment shall be made upon the first IND submission (which was submitted in March 2016). It had erroneously stated that the research and development expenses were $0 and $0 for the nine months ended June 30, 2016. Instead, our research and development expenses were $6,500,000 and $10,000,000 for the nine months ended June 30, 2016. The Company restated the consolidated financial statements for the above period in order to record the related liability and expense in the correct period, as well as providing necessary revision for the footnotes of related parties transactions and commitments and contingencies to reflect a more accurate disclosure. No other sections were affected, but for the convenience of the reader, the Company included the following tables that present the effect of the correction discussed above and other adjustments on selected line items of our previously reported consolidated financial statements as of and for the period ended June 30, 2016. For presentation purpose, certain items on the consolidated statements of cash flow for the period ended June 30, 2016 were changed according to the changes in the consolidated balance sheet. In addition, certain items were reclassified from financing activities to operating activities or from operating activities to financing activities. Details of changes are presented in the following tables. As of and for the Period Ended ITEMS Previously Adjustments Restated Consolidated Statements of Balance Sheets Prepayment 3,500,000 (3,500,000 ) - Due to related party - 6,500,000 6,500,000 Accumulated deficit (669,207 ) (10,000,000 ) (10,669,207 ) Consolidated Statements of Operations and Comprehensive Loss For the nine months ended June 30, 2016 Research and development expenses - 10,000,000 10,000,000 Net Loss (352,796 ) (10,000,000 ) (10,352,796 ) Basic and diluted loss per share (0.00 ) (0.05 ) (0.05 ) Consolidated Statements of Cash Flow Net loss from operating activities (353,605 ) (10,000,000 ) (10,353,605 ) Issuance of common stock for compensation - 897,521 897,521 (Increase) decreases in prepayment (3,496,185 ) 3,500,000 3,815 (Increase) decrease in due from related party 350,000 (350,000 ) - Increase (decrease) in due to related party (22,517 ) 6,500,000 6,477,483 Increase (decrease) in due to shareholder (46,586 ) 46,586 - Net cash used in operating activities (3,857,447 ) 594,107 (3,263,340 ) (Increase) decrease in due to shareholder - (46,586 ) (46,586 ) Proceeds from subscription receivable - 350,000 350,000 Proceeds from issuance of common stock 897,521 (897,521 ) - Net cash used in financing activities 2,947,521 (594,107 ) (2,353,414 ) The Company discovered that it had erroneously stated that the research and development expenses were understated during the year ended September 30, 2016. Instead, our research and development expenses were $10,000,000 for the year ended September 30, 2016 and were restated in the Adjustments No. 1 column. Moreover, there were typographical errors on Selling, General and Administration expenses which were corrected in the Adjustments No. 2 column. For the year ended September 30, 2015, the Net cash used in the operating activities was mistyped from $(715) to $(517) and was corrected in this restatement. The following tables present the effect of the corrections discussed above and other adjustments on selected line items of our previously reported consolidated financial statements as of and for the year ended September 30, 2016, Previously Adjustments No.1 Adjustments No.2 Restated Consolidated Balance Sheet As of September 30, 2016 Due to related party - 6,500,000 - 6,500,000 Total Liabilities 56,470 6,500,000 - 6,556,470 Additional paid-in capital 4,733,401 - 60 4,733,461 Accumulated deficit (4,823,401 ) (6,500,000 ) - (11,323,401 ) Total equity (deficit) 120,882 (6,500,000 ) - (6,379,118 ) Consolidated Statements of Operations and Comprehensive Loss For the year ended September 30, 2016 Selling, general and administrative expenses 4,497,263 (3,500,060 ) 60 997,263 Research and development expenses - 10,000,000 - 10,000,000 Net loss from operations (4,497,295 ) (6,499,940 ) (60 ) (10,997,295 ) Loss from continuing operations before income taxes (4,506,963 ) (6,499,940 ) (60 ) (11,006,963 ) Net Loss (4,507,799 ) (6,499,940 ) (60 ) (11,007,799 ) Basic and diluted loss per share (0.00 ) (0.06 ) (0.00 ) (0.06 ) Consolidated Statements of Cash Flow For the year ended September 30, 2016 Net loss from continuing operations (4,507,799 ) (6,499,940 ) (60 ) (11,007,799 ) Issuance of common stock for compensation 1,295,324 (60 ) 60 1,295,324 (Decrease) increase in due to related party (22,517 ) 6,500,000 6,477,483 Consolidated Statements of Cash Flow For the year ended September 30, 2015 Net cash used in operating activities (517 ) - (198 ) (715 ) As a result of the restatement of the consolidated balance sheets as of September 30, 2016, due to related party and total liabilities were increased by $6,500,000; changed from $0 to $6,500,000 and from $56,470 to $6,556,470. additional paid in capital was increased by $60 and changed from $4,733,401 to $4,733,461. Accumulated deficit was increased by $6,500,000 and changed from $(4,823,401) to $(11,323,401). Total equity (deficit) was decreased by $6,500,000 and changed from $120,882 to $(6,379,118). As a result of the restatement of the consolidated statements of operations and comprehensive loss for the year ended September 30, 2016, selling, general and administrative expenses were decreased by $3,500,000 and changed from $4,497,263 to $997,263. Research and development expenses were increased by $10,000,000 and changed from $0 to $10,000,000. Net loss from operations was increased by $6,500,000 and changed from $(4,497,295) to $(10,997,295) loss from continuing operations before taxes was increased by $6,500,000 and changed from $(4,506,963) to $(11,006,963). Net loss was increased by $6,500,000 and changed from $(4,507,799) to $(11,007,799). Basic and diluted loss per share were also increased by 0.06 and changed from $0 to $(0.06). As a result of the restatement of the consolidated statements of cash flow for the year ended September 30, 2016, net loss from continuing operations was increased by $6,500,000; changed from $(4,507,799) to $(11,007,799). Issuance of common stock for compensation did not have changes and stated as $1,295,324. (Decrease) increase in due to related party was increased by $6,500,000 and changed from $(22,517) to $6,477,483. There were no changes in net cash used in operating activities. As a result of the restatement of the consolidated statements of cash flow for the year ended September 30, 2015, Net cash used in operating activities was increased by $198 and changed from $(517) to $(715). Restatement for the period ended June 30, 2017 The Company determined that the total amount of $160,000, of which $70,000 was attributable to a consulting service provided to a Company’s shareholder, LionGene Corporation and $90,000 was as a result of the co-development with related party, Rgene Corporation (see Note 5 and Note 6) should be recorded as additional paid-in capital as of June 30, 2017 since the Company, LionGene Corporation, and Rgene Corporation are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation, and should be treated as the correction of error as of June 30, 2017. The Company restated the consolidated financial statements as of June 30, 2017 and for the three-month and nine-month period then ended. The item additional paid-in-capital adjusted up with $160,000 while the accumulated deficit adjusted down with ($160,000). Revenues, gross profit, net loss from operations, loss from continuing operations before income taxes, and net loss were also adjusted on the statement of operations for the three and nine months ended June 30, 2017 accordingly. Net loss from continuing operations, net cash used in operating activities, capital contribution form related parties under common control, and net cash provided by financing activities were also adjusted on the statements of cash flows for the nine months ended June 30, 2017 accordingly. ITEMS As of and for the Three and Nine Months Ended June 30, 2017 Previously Adjustments Restated Consolidated Balance Sheets Additional paid-in-capital 10,586,464 160,000 10,746,464 Accumulated deficit (11,848,288 ) (160,000 ) (12,008,288 ) Consolidated Statements of Operations For the three months ended June 30, 2017 Revenues 90,000 (90,000 ) - Gross profit 90,000 (90,000 ) - Net loss from operations (99,479 ) (90,000 ) (189,479 ) Loss from continuing operations before income taxes (127,879 ) (90,000 ) (217,879 ) Net loss (127,879 ) (90,000 ) (217,879 ) For the nine months ended June 30, 2017 Revenues 160,000 (160,000 ) - Gross profit 160,000 (160,000 ) - Net loss from operations (476,706 ) (160,000 ) (636,706 ) Loss from continuing operations before income taxes (524,057 ) (160,000 ) (684,057 ) Net loss (524,887 ) (160,000 ) (684,887 ) Consolidated Statements of Cash Flow For the nine months ended June 30, 2017 Cash flows from operating activities Net loss from continuing operations (524,887 ) (160,000 ) (684,887 ) Net cash used in operating activities (1,115,484 ) (160,000 ) (1,275,484 ) Cash flows from financing activities Capital contribution from related parties under common control - 160,000 160,000 Net cash provided by financing activities 950,000 160,000 1,110,000 As a result of the restatement of the consolidated balance sheets as of June 30, 2017, additional paid-in capital was increased by $160,000 and changed from $10,586,464 to $10,746,464. Accumulated deficit was increased by $160,000 and changed from $(11,848,288) to $(12,008,288). As a result of the restatement of the consolidated statements of operations for the three and nine months ended June 30, 2017, revenues were decreased by $90,000 and $160,000 and changed from $90,000 and $160,000 to $0 and $0, respectively. Gross profit was decreased by $90,000 and $160,000 and changed from $90,000 and $160,000 to $0 and $0, respectively. Net loss from operations was increased by $90,000 and $160,000 and changed from $(99,479) and $(476,706) to $(189,479) and $(636,706), respectively. Loss from continuing operations before income taxes was increased by $90,000 and $160,000 and changed from $(127,879) and $(524,057) to $(217,879) and $(684,057), respectively. Net loss was increased by $90,000 and $160,000 and changed from $(127,879) and $(524,887) to $(217,879) and $(684,887), respectively. Basic and diluted loss per share were also increased by 0.00 and changed from $(0.00) and $(0.00) to $(0.00) and $(0.00), respectively. As a result of the restatement of the consolidated statements of cash flow for the nine months ended June 30, 2017, net loss from continuing operations was increased by $160,000 and changed from $(524,887) to $(684,887). Net cash used in operating activities was increased by $160,000 and changed from $(1,115,484) to $(1,275,484). Capital contribution from related parties under common control under cash flows from financing activities was increased by $160,000 and changed from $0 to $160,000. Net cash provided by financing activities was increased by $160,000 and changed from $950,000 to $1,110,000.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2017
Summary of Significant Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying audited financial statements and related notes have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). This basis of accounting involves the application of accrual accounting. Consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars. The condensed financial statements include all adjustments that, in the opinion of management, are necessary in order not to make the financial statements misleading. Certain information and footnote disclosure normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The results of operations for the periods ended June 30, 2017 are not necessarily indicative of the operating results for the full year. Basis of Consolidation The consolidated financial statements include the financial statements of the Company and its subsidiary, BriVision. All intercompany transactions, balances and any unrealized profit and losses have been eliminated on consolidation. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results. Reclassifications We have reclassified certain prior period amounts within our consolidated financial statements and accompanying notes to conform to our current period presentation. These reclassifications did not affect total revenue, operating income, operating cash flows or net loss. Forward Stock split On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation. Fair Value Measurements The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value. There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of June 30, 2017. Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of June 30, 2017, the Company’s cash and cash equivalents amounted $8,053. As of September 30, 2016, the Company’s cash and cash equivalents amounted $173,537. All of the Company’s cash deposits are held in a financial institution located in where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality. Research and Development Expenses The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred. Stock-based Compensation The Company measures expense associated with all employee share-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation” The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 505-50 ”Equity-Based Payments to Non-Employees" which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Stock-based compensation expenses were recorded in general and administrative expenses and research and development expenses. Income Taxes The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain. Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred during the period from July 21, 2015 (inception) to June 30, 2017. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition. As of June 30, 2017 and June 30, 2016, the Company’s income tax expense amounted $830 and $836, respectively. Earnings Per Share of Common Stock The Company reports earnings (loss) per share in accordance with ASC Topic 260-10 "Earnings per Share." Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Commitments and Contingencies The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred. Recent Accounting Pronouncements Revenue Recognition: Revenue from Contracts with Customers: Topic Disclosure of Going Concern Uncertainties: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Leases Stock-based Compensation Financial Instruments - Credit Losses: Statement of Cash Flows: In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): “Restricted Cash”(“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016-18 will become effective for us beginning April 1, 2018, or fiscal 2019. ASU 2016-18 is required to be applied retrospectively. Upon the adoption, amounts described as restricted cash will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts shown on the statements of cash flows. Business Combination From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company's financial statements upon adoption. Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying financial statements.

Going Concern

Going Concern	9 Months Ended
	Jun. 30, 2017
Going Concern [Abstract]
GOING CONCERN	4. GOING CONCERN The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred losses since its inception resulting in an accumulated deficit of $12,008,288 as of June 30, 2017. The Company also incurred net losses of $684,887 and negative cash flow of $165,484 for the nine months ended June 30, 2017. The ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they become due. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company upon signing of that agreement. On May 6, 2016, we and BioLite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have agreed to pay the Milestone Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016. Pursuant to the Collaborative Agreement, 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. On February 2017, the Company agreed to pay this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of our common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. The cash payment and shares issuance were completed in February 2017. This Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term.

Collaborative Agreement

Collaborative Agreement	9 Months Ended
	Jun. 30, 2017
Collaborative Agreement [Abstract]
COLLABORATIVE AGREEMENT	5. COLLABORATIVE AGREEMENT On December 29, 2015, BriVision entered into a Collaborative Agreement with BioLite Inc., a related party, pursuant to which BioLite granted the Company sole licensing rights for drug and therapeutic use of five products: BLI-1005 CNS-Major Depressive Disorder; BLI-1008 CNS-Attention Deficit Hyperactivity Disorder; BLI-1401-1 Anti-Tumor Combination Therapy-Solid Tumor with Anti-PD-1; BLI-1401-2 Anti-Tumor Combination Therapy-Triple Negative Breast Cancer; and BLI-1501 Hematology-Chronic Lymphocytic Leukemia, in USA and Canada. Under the Collaborative Agreement, BriVision should pay a total of $100,000,000 in cash or stock of BriVision with equivalent value, according to the following schedule: ● upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week. ● upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week. ● at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months. ● upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week. ● at the completion of phase III, BriVision shall pay, but no later than September 15, 2019: 25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months. ● upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week. Pursuant to the Collaborative Agreement, an upfront payment of $3,500,000 (the “Milestone Payment”), which is 3.5% of total payments due under the Collaborative Agreement, was to be paid by the Company upon signing of that agreement. On May 6, 2016, BriVision and BioLite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have agreed to pay the Milestone Payment to BioLite $2,600,000 in cash and $900,000 in newly issued shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares. The cash payment and shares issuance were completed in June 2016. Pursuant to the Collaborative Agreement, 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of our common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. This Collaborative Agreement shall, once signed by both Parties, remain in effect for fifteen years as of the first commercial sales of the Product in the Territory and automatically renew for five more years unless either party gives the other party six month written notice of termination prior to the expiration date of the term. The Company determined to fully expense the entire amount of $10,000,000 since currently the related licensing rights do not have alternative future uses. According to ASC 730-10-25-1, absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses immediately. Hence, the entire amount is fully expensed as research and development expense. On January 12, 2017, BriVision entered into an addendum (the “Addendum”) to the Collaborative Agreement (collectively, the “Latest Collaborate Agreement”). On May 26, 2017, we entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene Corporation, a corporation incorporated under the laws of Taiwan (“Rgene”), to co-develop and commercialize certain products that are included in the Sixth Product as defined in the Addendum. Under the terms of the Co-Dev Agreement, Rgene will pay to the Company $3,000,000 in cash or stock by August 15, 2017 in three installments. During the nine months ended June 30, 2017, the Company has received $90,000 in cash. We are still in discussion with Rgene with respect to the schedule of the outstanding balance. The Company is entitled to receive 50% of the future net licensing income or net sales profit, if any, and any development cost shall be equally shared by both Parties.

Related Parties Balances and Tr

Related Parties Balances and Transactions	9 Months Ended
	Jun. 30, 2017
Related Parties Balances and Transactions [Abstract]
RELATED PARTIES BALANCES AND TRANSACTIONS	6. RELATED PARTIES BALANCES AND TRANSACTIONS The following is a list of related parties to which the Company has transactions with: Eugene Jiang is the Chief Executive Officer of the Company, the owner of BioLite, Inc and one of the directors and common stock shareholders of BioFirst Corporation. Amount due to related party Amount due to related party consisted of the following as of the periods indicated: June 30, September 30, BioLite, Inc $ - $ 6,500,000 BioFirst Corporation 950,000 - YuanGene Corporation 3,000 - Balance as at the ended of the period / year $ 953,000 $ 6,500,000 Related party transactions Unsecured borrowings from related parties consisted of the following for the periods indicated: June 30, September 30, BioFirst Corporation $ 950,000 $ - YuanGene Corporation 3,000 - Total $ 953,000 $ - On January 26, 2017, the Company entered into a loan agreement with the lender party thereto, BioFirst Corporation, a company incorporated in Taiwan, Republic of China, for a total commitment (non-secured indebtedness) of $950,000 to meet its working capital needs. Under the terms of the loan agreement, the loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to remit the interest payment monthly to the lender. The loan will be matured on February 1, 2018. Interest expense related to this indebtedness is $28,500 and $0 for the three months ended June 30, 2017 and 2016, respectively and $47,500 and $0 for the nine months ended June 30, 2017 and 2016, respectively. Accrued interest related to this borrowing is $9,500 and $0 as of June 30, 2017 and September 30, 2016, respectively. During the nine months ended June 30, 2017, the Company provided a one-time consulting service to LionGene Corporation for $70,000. Since both LionGene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation, the Company has recorded the full amount of $70,000 as additional paid-in capital during the nine months ended June 30, 2017. On May 26, 2017, BriVision entered into a co-development agreement (the “Co-Dev Agreement”) with Rgene (See Note 5). As of June 30, 2017, the Company has received an aggregate amount of $90,000 in cash. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation, the Company has recorded the cash receipt of $90,000 in connection with the Co-Dev Agreement as additional paid-in capital during the nine months ended June 30, 2017.

Accrued Expenses and Other Paya

Accrued Expenses and Other Payables	9 Months Ended
	Jun. 30, 2017
Accrued Expenses and Other Payables [Abstract]
ACCRUED EXPENSES AND OTHER PAYABLES	7. ACCRUED EXPENSES AND OTHER PAYABLES Accrued expenses and other payables as of June 30, 2017 and September 30, 2016 consisted of: June 30, September 30, Accruals for consulting fee $ 31,640 $ 23,100 Accruals for audit fee 19,000 15,000 Accruals for interest expense 9,500 - Accruals for rental expense 42,990 - Total accrued expenses and other payables $ 103,130 $ 38,100

Equity

Equity	9 Months Ended
	Jun. 30, 2017
Equity [Abstract]
EQUITY	8. EQUITY During October 2015, $350,000 of subscription receivable was fully collected from the shareholders. On February 8, 2016, a Share Exchange Agreement (“Share Exchange Agreement”) was entered into by and among the Company, BriVision, Euro-Asia Investment & Finance Corp. Limited, a company incorporated under the laws of Hong Kong Special Administrative Region of People's Republic of China (“Euro-Asia”), being the owners of record of 164,387,376 (52,336,000 pre-stock split) shares of common stock of the Company, and the owners of record of all of the issued share capital of BriVision (the “BriVision Stock”). Pursuant to the Share Exchange Agreement, upon surrender by the BriVision Shareholders and the cancellation by BriVision of the certificates evidencing the BriVision Stock as registered in the name of each BriVision Shareholder, and pursuant to the registration of the Company in the register of members maintained by BriVision as the new holder of the BriVision Stock and the issuance of the certificates evidencing the aforementioned registration of the BriVision Stock in the name of the Company, the Company should issue 166,273,921 (52,936,583 pre-stock split) shares (the “Acquisition Stock”) (subject to adjustment for fractionalized shares as set forth below) of the Company’s common stock to the BriVision Shareholders (or their designees), and 163,159,952 (51,945,225 pre-stock split) shares of the Company’s common stock owned by Euro-Asia should be cancelled and retired to treasury. The Acquisition Stock collectively should represent 79.70% of the issued and outstanding common stock of the Company immediately after the Closing, in exchange for the BriVision Stock, representing 100% of the issued share capital of BriVision in a reverse merger, or the Merger. Pursuant to the Merger, all of the issued and outstanding shares of BriVision’s common stock were converted, at an exchange ratio of 0.2536-for-1, into an aggregate of 166,273,921(52,936,583 pre-stock split) shares of Company’s common stock and BriVision became a wholly owned subsidiary, of the Company. The holders of Company’s common stock as of immediately prior to the Merger held an aggregate of 205,519,223 (65,431,144 pre-stock split) shares of Company’s common stock, Because of the exchange of the BriVision Stock for the Acquisition Stock (the “Share Exchange”), BriVision became a wholly owned subsidiary (the “Subsidiary”) of the Company and there was a change of control of the Company following the closing. There were no warrants, options or other equity instruments issued in connection with the share exchange agreement. On February 17, 2016, pursuant to the 2016 Equity Incentive Plan (the “2016 Plan”), 157,050 (50,000 pre-stock split) shares were granted to the employees. On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to affect a forward split at a ratio of 1 to 3.141 (the “Forward Stock Split”) and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation. On May 6, 2016, BriVision and BioLite agreed to amend the Collaborative Agreement, through entry into the Milestone Payment Agreement, whereby we have agreed to issue shares of our common stock, at the price of $1.60 per share, for an aggregate number of 562,500 shares, as part of our first installation of payment pursuant to the Milestone Payment. The shares issuance was completed in June 2016. On August 26, 2016, the Company issued 1,468,750 shares (“Shares”) of the Company’s common stock, par value $0.001 (the “Offering”) to BioLite, Inc., a non-U.S. accredited investor (the “Purchaser”) pursuant to a certain Stock Purchase Agreement dated August 26, 2016 (the “SPA”). The Shares are exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Regulation S of the Securities Act promulgated thereunder. Our sole director, Eugene Jiang, is a director of BioLite and it is therefore considered a related party. The purchase price per share of the Offering is $1.60. The net proceeds to the Company from the Offering are approximately $2,350,000. The proceeds may be used for general corporate purposes. Pursuant to the Collaborative Agreement with BioLite, Inc. a related party, as discussed in Note 5 above, BriVision should pay a total of $100,000,000 in cash or stock of BriVision with equivalent value according to the milestone achieved. The agreement requires that 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of our common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares. On October 1, 2016, the Company entered into a Consulting Agreement with Kazunori Kameyama (“Kameyama”) for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company’s common stock at $1.00 per share for any amount exceeding $3,000. The Company’s stocks will be calculated and issued in December every year. The contract will be terminated on September 30, 2017. For the nine months ended on June 30, 2017, the Company recognized (as appropriate relative to the periods and manner that the Company would recognize cash payments under the same arrangement) the cost of the appropriate number of the 1,688 shares at the current fair value as of December 31, 2016 and June 30, 2017. The stock-based compensation related to this consulting agreement was $5,928 for the nine months ended on June 30, 2017. Pursuant to ASC 505-50-30, the transactions with the non-employees were measured based on the fair value of the equity instruments issued as the Company determined that the fair value of the equity instruments issued in a share-based payment transaction with nonemployees was more reliably measurable than the fair value of the consideration received. The Company measured the fair value of the equity instruments in these transactions using the stock price on the date at which Kameyama’s commitment for performance is reached.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
EARNINGS PER SHARE	9. EARNINGS PER SHARE Basic earnings per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the year. Diluted earnings per share is computed by dividing net loss by the weighted-average number of common shares and dilutive potential common shares outstanding during the year. For the For the For the Nine Months Ended June 30, For the Nine Months Ended June 30, 2017 2016 2017 2016 (Restated) (Restated) Numerator: Net loss $ (217,879 ) $ (293,237 ) $ (684,887 ) $ (10,353,605 ) Denominator: Weighted-average shares outstanding: Weighted-average shares outstanding – Basic & Diluted 213,746,647 208,779,424 212,203,790 208,779,424 Earnings per share -Basic & Diluted (0.00 ) (0.00 ) (0.00 ) (0.05 ) Diluted earnings per share takes into account the potential dilution that could occur if securities or other contracts to issue common stock were exercised and converted into common stock.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 30, 2017
Commitments and Contingencies [Abstract]
COMMITMENTS AND CONTINGENCIES	10 . COMMITMENTS AND CONTINGENCIES Operating Commitment The total future minimum lease payments under the non-cancellable operating lease with respect to the office as of June 30, 2017 are payable as follows: Year ending September 30, 2017 14,802 Total $ 14,802 Rental expense of the Company was $23,640 and $7,727 for the three months ended June 30, 2017 and 2016, respectively, and $56,380 and $20,291 for the nine months ended June 30, 2017 and 2016, respectively.

Subsequent Event

Subsequent Event	9 Months Ended
	Jun. 30, 2017
Subsequent Event [Abstract]
SUBSEQUENT EVENT	11. SUBSEQUENT EVENT On July 24, 2017, the Company entered into a collaborative agreement (the “Collaborative Agreement”) with BioFirst Corporation (“BioFirst”), a corporation incorporated under the laws of Taiwan, pursuant to which BioFirst granted us the global license for medical use of the product (the “Product”): BFC-1401 Vitreous Substitute for Vitrectomy. BioFirst is a related party to the Company as Eugene Jiang, Chief Executive Officer of the Company, is one of the directors and common stock shareholders of BioFirst. According to the Collaborative Agreement, we will co-develop and commercialize the Product with BioFirst and pay BioFirst $3,000,000 (the “Total Payment”) in cash or stock by September 30, 2018 in two installments. An upfront payment of $300,000, representing 10% of the Total Payment due under the Collaborative Agreement, was paid by us upon signing of the Collaborative Agreement. No payment has incurred as of this quarterly report. The Company is entitled to receive 50% of the future net licensing income

Summary of Significant Accoun17

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2017
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying audited financial statements and related notes have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S. GAAP). This basis of accounting involves the application of accrual accounting. Consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred. The Company’s financial statements are expressed in U.S. dollars. The condensed financial statements include all adjustments that, in the opinion of management, are necessary in order not to make the financial statements misleading. Certain information and footnote disclosure normally included in financial statements prepared in accordance with US GAAP have been condensed or omitted. The results of operations for the periods ended June 30, 2017 are not necessarily indicative of the operating results for the full year.
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the financial statements of the Company and its subsidiary, BriVision. All intercompany transactions, balances and any unrealized profit and losses have been eliminated on consolidation.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.
Reclassifications	Reclassifications We have reclassified certain prior period amounts within our consolidated financial statements and accompanying notes to conform to our current period presentation. These reclassifications did not affect total revenue, operating income, operating cash flows or net loss.
Forward Stock split	Forward Stock split On March 21, 2016, the Board of Directors of the Company approved an amendment to Articles of Incorporation to effect a forward split at a ratio of 1 to 3.141 and increase the number of our authorized shares of common stock, par value $0.001 per share, to 360,000,000, which was effective on April 8, 2016. The majority of the shareholders of the Company approved the amendment to Articles of Incorporation.
Fair Value Measurements	Fair Value Measurements The Company applies the provisions of ASC Subtopic 820-10, “Fair Value Measurements”, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, the Company considers the principal or most advantageous market in which it would transact and it considers assumptions that market participants would use when pricing the asset or liability. ASC 820 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes three levels of inputs to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows: ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the assets or liability, either directly or indirectly, for substantially the full term of the financial instruments. ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value. There were no assets or liabilities measured at fair value on a recurring basis subject to the disclosure requirements of ASC 820 as of June 30, 2017.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of June 30, 2017, the Company’s cash and cash equivalents amounted $8,053. As of September 30, 2016, the Company’s cash and cash equivalents amounted $173,537. All of the Company’s cash deposits are held in a financial institution located in where there is currently regulation mandated on obligatory insurance of bank accounts. The Company believes this financial institution is of high credit quality.
Research and Development Expenses	Research and Development Expenses The Company accounts for the cost of using licensing rights in research and development cost according to ASC Topic 730-10-25-1. This guidance provides that absent alternative future uses the acquisition of product rights to be used in research and development activities must be charged to research and development expenses when incurred.
Stock-based Compensation	Stock-based Compensation The Company measures expense associated with all employee share-based compensation awards using a fair value method and recognizes such expense in the consolidated financial statements on a straight-line basis over the requisite service period in accordance with ASC Topic 718 “Compensation-Stock Compensation” The Company accounted for stock-based compensation to non-employees in accordance with ASC Topic 505-50 ”Equity-Based Payments to Non-Employees" which requires that the cost of services received from non-employees is measured at fair value at the earlier of the performance commitment date or the date service is completed and recognized over the period the service is provided. Stock-based compensation expenses were recorded in general and administrative expenses and research and development expenses.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability approach which allows the recognition and measurement of deferred tax assets to be based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will expire before the Company is able to realize their benefits, or future deductibility is uncertain. Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The evaluation of a tax position is a two-step process. The first step is to determine whether it is more-likely-than-not that a tax position will be sustained upon examination, including the resolution of any related appeals or litigations based on the technical merits of that position. The second step is to measure a tax position that meets the more-likely-than-not threshold to determine the amount of benefits recognized in the financial statements. A tax position is measured at the largest amount of benefit that is greater than 50 percent likely of being realized upon ultimate settlement. Tax positions that previously failed to meet the more-likely-than-not recognition threshold should be recognized in the first subsequent period in which the threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not criteria should be de-recognized in the first subsequent financial reporting period in which the threshold is no longer satisfied. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the year incurred. No significant penalty or interest relating to income taxes has been incurred during the period from July 21, 2015 (inception) to June 30, 2017. GAAP also provides guidance on de-recognition, classification, interest and penalties, accounting in interim periods, disclosures and transition. As of June 30, 2017 and June 30, 2016, the Company’s income tax expense amounted $830 and $836, respectively.
Earnings Per Share of Common Stock	Earnings Per Share of Common Stock The Company reports earnings (loss) per share in accordance with ASC Topic 260-10 "Earnings per Share." Basic earnings (loss) per share are computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available.
Commitments and Contingencies	Commitments and Contingencies The Company has adopted ASC Topic 450 “Contingencies” subtopic 20, in determining its accruals and disclosures with respect to loss contingencies. Accordingly, estimated losses from loss contingencies are accrued by a charge to income when information available before financial statements are issued or are available to be issued indicates that it is probable that an assets had been impaired or a liability had been incurred at the date of the financial statements and the amount of the loss can be reasonably estimated. Legal expenses associated with the contingency are expensed as incurred. If a loss contingency is not probable or reasonably estimable, disclosure of the loss contingency is made in the financial statements when it is at least reasonably possible that a material loss could be incurred.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Revenue Recognition: Revenue from Contracts with Customers: Topic Disclosure of Going Concern Uncertainties: Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Leases Stock-based Compensation Financial Instruments - Credit Losses: Statement of Cash Flows: In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): “Restricted Cash”(“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. ASU 2016-18 will become effective for us beginning April 1, 2018, or fiscal 2019. ASU 2016-18 is required to be applied retrospectively. Upon the adoption, amounts described as restricted cash will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period amounts shown on the statements of cash flows. Business Combination From time to time, new accounting pronouncements are issued by FASB that are adopted by the Company as of the specified effective date. If not discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on the Company's financial statements upon adoption. Management does not believe that any recently issued, but not yet effective accounting pronouncements, when adopted, will have a material effect on the accompanying financial statements

Corrections to Previously Iss18

Corrections to Previously Issued Consolidated Financial Statements (Tables)	9 Months Ended
	Jun. 30, 2017
Corrections to Previously Issued Consolidated Financial Statements [Abstract]
Schedule of corrections and consolidated financial statements	As of and for the Period Ended ITEMS Previously Adjustments Restated Consolidated Statements of Balance Sheets Prepayment 3,500,000 (3,500,000 ) - Due to related party - 6,500,000 6,500,000 Accumulated deficit (669,207 ) (10,000,000 ) (10,669,207 ) Consolidated Statements of Operations and Comprehensive Loss For the nine months ended June 30, 2016 Research and development expenses - 10,000,000 10,000,000 Net Loss (352,796 ) (10,000,000 ) (10,352,796 ) Basic and diluted loss per share (0.00 ) (0.05 ) (0.05 ) Consolidated Statements of Cash Flow Net loss from operating activities (353,605 ) (10,000,000 ) (10,353,605 ) Issuance of common stock for compensation - 897,521 897,521 (Increase) decreases in prepayment (3,496,185 ) 3,500,000 3,815 (Increase) decrease in due from related party 350,000 (350,000 ) - Increase (decrease) in due to related party (22,517 ) 6,500,000 6,477,483 Increase (decrease) in due to shareholder (46,586 ) 46,586 - Net cash used in operating activities (3,857,447 ) 594,107 (3,263,340 ) (Increase) decrease in due to shareholder - (46,586 ) (46,586 ) Proceeds from subscription receivable - 350,000 350,000 Proceeds from issuance of common stock 897,521 (897,521 ) - Net cash used in financing activities 2,947,521 (594,107 ) (2,353,414 ) ITEMS As of and for the Three and Nine Months Ended June 30, 2017 Previously Adjustments Restated Consolidated Balance Sheets Additional paid-in-capital 10,586,464 160,000 10,746,464 Accumulated deficit (11,848,288 ) (160,000 ) (12,008,288 ) Consolidated Statements of Operations For the three months ended June 30, 2017 Revenues 90,000 (90,000 ) - Gross profit 90,000 (90,000 ) - Net loss from operations (99,479 ) (90,000 ) (189,479 ) Loss from continuing operations before income taxes (127,879 ) (90,000 ) (217,879 ) Net loss (127,879 ) (90,000 ) (217,879 ) For the nine months ended June 30, 2017 Revenues 160,000 (160,000 ) - Gross profit 160,000 (160,000 ) - Net loss from operations (476,706 ) (160,000 ) (636,706 ) Loss from continuing operations before income taxes (524,057 ) (160,000 ) (684,057 ) Net loss (524,887 ) (160,000 ) (684,887 ) Consolidated Statements of Cash Flow For the nine months ended June 30, 2017 Cash flows from operating activities Net loss from continuing operations (524,887 ) (160,000 ) (684,887 ) Net cash used in operating activities (1,115,484 ) (160,000 ) (1,275,484 ) Cash flows from financing activities Capital contribution from related parties under common control - 160,000 160,000 Net cash provided by financing activities 950,000 160,000 1,110,000 As a result of the restatement of the consolidated
Schedule of adjustments on previously reported consolidated financial statements	Previously Reported on Form 10K Adjustments No.1 Adjustments No.2 Restated Consolidated Balance Sheet As of September 30, 2016 Due to related party - 6,500,000 - 6,500,000 Total Liabilities 56,470 6,500,000 - 6,556,470 Additional paid-in capital 4,733,401 - 60 4,733,461 Accumulated deficit (4,823,401 ) (6,500,000 ) - (11,323,401 ) Total equity (deficit) 120,882 (6,500,000 ) - (6,379,118 ) Consolidated Statements of Operations and Comprehensive Loss For the year ended September 30, 2016 Selling, general and administrative expenses 4,497,263 (3,500,060 ) 60 997,263 Research and development expenses - 10,000,000 - 10,000,000 Net loss from operations (4,497,295 ) (6,499,940 ) (60 ) (10,997,295 ) Loss from continuing operations before income taxes (4,506,963 ) (6,499,940 ) (60 ) (11,006,963 ) Net Loss (4,507,799 ) (6,499,940 ) (60 ) (11,007,799 ) Basic and diluted loss per share (0.00 ) (0.06 ) (0.00 ) (0.06 ) Consolidated Statements of Cash Flow For the year ended September 30, 2016 Net loss from continuing operations (4,507,799 ) (6,499,940 ) (60 ) (11,007,799 ) Issuance of common stock for compensation 1,295,324 (60 ) 60 1,295,324 (Decrease) increase in due to related party (22,517 ) 6,500,000 6,477,483 Consolidated Statements of Cash Flow For the year ended September 30, 2015 Net cash used in operating activities (517) - (198 ) (7 )

Related Parties Balances and 19

Related Parties Balances and Transactions (Tables)	9 Months Ended
	Jun. 30, 2017
Related Parties Balances and Transactions [Abstract]
Schedule of amount due to related party	June 30, September 30, BioLite, Inc $ - $ 6,500,000 BioFirst Corporation 950,000 - YuanGene Corporation 3,000 - Balance as at the ended of the period / year $ 953,000 $ 6,500,000
Schedule of related party transactions	June 30, September 30, BioFirst Corporation $ 950,000 $ - YuanGene Corporation 3,000 - Total $ 953,000 $ -

Accrued Expenses and Other Pa20

Accrued Expenses and Other Payables (Tables)	9 Months Ended
	Jun. 30, 2017
Accrued Expenses and Other Payables [Abstract]
Schedule of accrued expenses and other payables	June 30, September 30, Accruals for consulting fee $ 31,640 $ 23,100 Accruals for audit fee 19,000 15,000 Accruals for interest expense 9,500 - Accruals for rental expense 42,990 - Total accrued expenses and other payables $ 103,130 $ 38,100

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Schedule of earnings per share	For the For the For the Nine Months Ended June 30, For the Nine Months Ended June 30, 2017 2016 2017 2016 (Restated) (Restated) Numerator: Net loss $ (217,879 ) $ (293,237 ) $ (684,887 ) $ (10,353,605 ) Denominator: Weighted-average shares outstanding: Weighted-average shares outstanding – Basic & Diluted 213,746,647 208,779,424 212,203,790 208,779,424 Earnings per share -Basic & Diluted (0.00 ) (0.00 ) (0.00 ) (0.05 )

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Jun. 30, 2017
Commitments and Contingencies [Abstract]
Schedule of total future minimum lease payments under non-cancellable operating lease	Year ending September 30, 2017 14,802 Total $ 14,802

Organization and Description 23

Organization and Description of Business (Details) - Share Exchange Agreement [Member]	Feb. 08, 2016shares
Organization and Description of Business (Textual)
Issued common stock, shares	52,336,000
Acquisition stock, shares	52,936,583
Percentage of common shares issued and outstanding	79.70%
Percentage of issued share capital	100.00%
Euro-Asia [Member]
Organization and Description of Business (Textual)
Issued common stock, shares	51,945,225
American BriVision (Holding) Corporation [Member]
Organization and Description of Business (Textual)
Percentage of common shares issued and outstanding	79.70%

Corrections to Previously Iss24

Corrections to Previously Issued Consolidated Financial Statements (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
Consolidated Statements of Balance Sheets
Due to related party	$ 953,000		$ 953,000		$ 6,500,000
Additional Paid in Capital	10,746,464		10,746,464		4,733,461
Accumulated deficit	(12,008,288)		(12,008,288)		(11,323,401)
Consolidated Statements of Operations and Comprehensive Loss
Revenues
Gross Profit				(32)
Research and development expenses	17,500		67,848	10,000,000
Net loss from operations	(189,479)	(289,098)	(636,706)	(10,349,518)
Loss from continuing operations before income taxes	(217,879)	(292,401)	(684,057)	(10,352,769)
Net Loss	$ (217,879)	$ (293,237)	$ (684,887)	$ (10,353,605)
Basic and diluted loss per share	$ 0	$ 0	$ 0	$ (0.05)
Consolidated Statements of Cash Flow
Net loss from operating activities	$ (217,879)	$ (293,237)	$ (684,887)	$ (10,353,605)
Issuance of common stock for compensation	2,552		5,928
(Increase) decreases in prepayment				3,815
(Increase) decrease in due from related party
Increase (decrease) in due to related party			(647,000)	6,477,483
Increase (decrease) in due to shareholder				(46,586)
Net cash used in operating activities			(1,275,484)	(3,263,340)
Proceeds from subscription receivable				350,000
Capital contribution from related parties under common control			160,000
Payments For Financing Activities			1,110,000	2,353,414
Previously Reported [Member]
Consolidated Statements of Balance Sheets
Prepayment		3,500,000		3,500,000
Due to related party
Additional Paid in Capital	10,586,464		10,586,464		4,733,401
Accumulated deficit	(11,848,288)	(669,207)	(11,848,288)	(669,207)	(4,823,401)
Consolidated Statements of Operations and Comprehensive Loss
Revenues	90,000		160,000
Gross Profit	90,000		160,000
Research and development expenses
Net loss from operations	(99,479)		(476,706)		(4,497,295)
Loss from continuing operations before income taxes	(217,879)		(524,057)		(4,506,963)
Net Loss	(217,879)		(524,887)	$ (353,605)	$ (4,507,799)
Basic and diluted loss per share					$ 0
Consolidated Statements of Cash Flow
Cash flows from operating activities
Net loss from operating activities	(217,879)		(524,887)	$ (353,605)	$ (4,507,799)
Issuance of common stock for compensation
(Increase) decreases in prepayment				(3,496,185)
(Increase) decrease in due from related party				350,000
Increase (decrease) in due to related party				(22,517)	(22,517)
Increase (decrease) in due to shareholder				(46,586)
Net cash used in operating activities			(1,115,484)	(3,857,447)		$ (517)
(Increase) decrease in due to shareholder
Proceeds from subscription receivable
Proceeds from issuance of common stock				897,521
Proceeds From Financing Activities
Capital contribution from related parties under common control
Payments For Financing Activities			950,000	2,947,521
Adjustments [Member]
Consolidated Statements of Balance Sheets
Prepayment		(3,500,000)		(3,500,000)
Due to related party		6,500,000		6,500,000	6,500,000
Additional Paid in Capital	160,000		160,000
Accumulated deficit	(160,000)	(10,000,000)	(160,000)	(10,000,000)	(6,500,000)
Consolidated Statements of Operations and Comprehensive Loss
Revenues	(90,000)		(160,000)
Gross Profit	(90,000)		(160,000)
Research and development expenses			10,000,000		10,000,000
Net loss from operations	(90,000)		(160,000)		(6,499,940)
Loss from continuing operations before income taxes	(90,000)		(160,000)		(6,499,940)
Net Loss	(90,000)		(160,000)	$ (10,000,000)	$ (6,499,940)
Basic and diluted loss per share				$ (0.05)	$ (0.06)
Consolidated Statements of Cash Flow
Cash flows from operating activities
Net loss from operating activities	(90,000)		(160,000)	$ (10,000,000)	$ (6,499,940)
Issuance of common stock for compensation				897,521
(Increase) decreases in prepayment				3,500,000
(Increase) decrease in due from related party				(350,000)
Increase (decrease) in due to related party				6,500,000	6,500,000
Increase (decrease) in due to shareholder				46,586
Net cash used in operating activities			(160,000)	594,107
(Increase) decrease in due to shareholder				46,586
Proceeds from subscription receivable				350,000
Proceeds from issuance of common stock				(897,521)
Proceeds From Financing Activities
Capital contribution from related parties under common control			160,000
Payments For Financing Activities			160,000	(594,107)
Restated [Member]
Consolidated Statements of Balance Sheets
Prepayment
Due to related party		6,500,000		6,500,000	6,500,000
Additional Paid in Capital	10,746,464		10,746,464		4,733,461
Accumulated deficit	(12,008,288)	$ (10,669,207)	(12,008,288)	(10,669,207)	(11,323,401)
Consolidated Statements of Operations and Comprehensive Loss
Revenues
Gross Profit
Research and development expenses			10,000,000		10,000,000
Net loss from operations	(189,479)		(636,706)		(10,997,295)
Loss from continuing operations before income taxes	(217,879)		(684,057)		(11,006,963)
Net Loss	(217,879)		(684,887)	$ (10,353,605)	$ (11,007,799)
Basic and diluted loss per share				$ (0.05)	$ (0.06)
Consolidated Statements of Cash Flow
Cash flows from operating activities
Net loss from operating activities	$ (217,879)		(684,887)	$ (10,353,605)	$ (11,007,799)
Issuance of common stock for compensation				897,521
(Increase) decreases in prepayment				3,815
(Increase) decrease in due from related party
Increase (decrease) in due to related party				6,477,483	$ 6,477,483
Increase (decrease) in due to shareholder
Net cash used in operating activities			(1,275,484)	(3,263,340)		$ (715)
(Increase) decrease in due to shareholder				(46,586)
Proceeds from subscription receivable				350,000
Proceeds from issuance of common stock
Proceeds From Financing Activities
Capital contribution from related parties under common control			160,000
Payments For Financing Activities			$ 1,110,000	$ (2,353,414)

Corrections to Previously Iss25

Corrections to Previously Issued Consolidated Financial Statements (Details 1) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
Consolidated Balance Sheet
Due to related party	$ 953,000		$ 953,000		$ 6,500,000
Total liabilities	1,056,130		1,056,130		6,556,470
Additional paid-in capital	10,746,464		10,746,464		4,733,461
Accumulated deficit	(12,008,288)		(12,008,288)		(11,323,401)
Total equity (deficit)	(1,048,077)		(1,048,077)		(6,379,118)
Consolidated Statements of Operations and Comprehensive Loss
Selling, general and administrative expenses	169,427	$ 289,098	562,930	$ 349,486
Research and development expenses	17,500		67,848	10,000,000
Net loss from operations	(189,479)	(289,098)	(636,706)	(10,349,518)
Loss from continuing operations before income taxes	(217,879)	(292,401)	(684,057)	(10,352,769)
Net Loss	$ (217,879)	$ (293,237)	$ (684,887)	$ (10,353,605)
Basic and diluted loss per share	$ 0	$ 0	$ 0	$ (0.05)
Consolidated Statements of Cash Flow
Net loss from operating activities	$ (217,879)	$ (293,237)	$ (684,887)	$ (10,353,605)
Issuance of common stock for compensation
(Decrease) increase in due to related party			(647,000)	6,477,483
Net cash used in operating activities			(1,275,484)	(3,263,340)
Previously Reported on Form 10K [Member]
Consolidated Balance Sheet
Due to related party
Total liabilities					56,470
Additional paid-in capital	10,586,464		10,586,464		4,733,401
Accumulated deficit	(11,848,288)	(669,207)	(11,848,288)	(669,207)	(4,823,401)
Total equity (deficit)					120,882
Consolidated Statements of Operations and Comprehensive Loss
Selling, general and administrative expenses					4,497,263
Research and development expenses
Net loss from operations	(99,479)		(476,706)		(4,497,295)
Loss from continuing operations before income taxes	(217,879)		(524,057)		(4,506,963)
Net Loss	(217,879)		(524,887)	$ (353,605)	$ (4,507,799)
Basic and diluted loss per share					$ 0
Consolidated Statements of Cash Flow
Net loss from operating activities	(217,879)		(524,887)	$ (353,605)	$ (4,507,799)
Issuance of common stock for compensation					1,295,324
(Decrease) increase in due to related party				(22,517)	(22,517)
Net cash used in operating activities			(1,115,484)	(3,857,447)		$ (517)
Adjustments No.1 [Member]
Consolidated Balance Sheet
Due to related party		6,500,000		6,500,000	6,500,000
Total liabilities					6,500,000
Additional paid-in capital	160,000		160,000
Accumulated deficit	(160,000)	(10,000,000)	(160,000)	(10,000,000)	(6,500,000)
Total equity (deficit)					(6,500,000)
Consolidated Statements of Operations and Comprehensive Loss
Selling, general and administrative expenses					(3,500,060)
Research and development expenses			10,000,000		10,000,000
Net loss from operations	(90,000)		(160,000)		(6,499,940)
Loss from continuing operations before income taxes	(90,000)		(160,000)		(6,499,940)
Net Loss	(90,000)		(160,000)	$ (10,000,000)	$ (6,499,940)
Basic and diluted loss per share				$ (0.05)	$ (0.06)
Consolidated Statements of Cash Flow
Net loss from operating activities	(90,000)		(160,000)	$ (10,000,000)	$ (6,499,940)
Issuance of common stock for compensation					(60)
(Decrease) increase in due to related party				6,500,000	6,500,000
Net cash used in operating activities			(160,000)	594,107
Adjustments No.2 [Member]
Consolidated Balance Sheet
Due to related party
Total liabilities
Additional paid-in capital					60
Accumulated deficit
Total equity (deficit)
Consolidated Statements of Operations and Comprehensive Loss
Selling, general and administrative expenses					60
Research and development expenses
Net loss from operations					(60)
Loss from continuing operations before income taxes					(60)
Net Loss					$ (60)
Basic and diluted loss per share					$ 0
Consolidated Statements of Cash Flow
Net loss from operating activities					$ (60)
Issuance of common stock for compensation					60
(Decrease) increase in due to related party
Net cash used in operating activities						(198)
Restated [Member]
Consolidated Balance Sheet
Due to related party		6,500,000		6,500,000	6,500,000
Total liabilities					6,556,470
Additional paid-in capital	10,746,464		10,746,464		4,733,461
Accumulated deficit	(12,008,288)	$ (10,669,207)	(12,008,288)	(10,669,207)	(11,323,401)
Total equity (deficit)					(6,379,118)
Consolidated Statements of Operations and Comprehensive Loss
Selling, general and administrative expenses					997,263
Research and development expenses			10,000,000		10,000,000
Net loss from operations	(189,479)		(636,706)		(10,997,295)
Loss from continuing operations before income taxes	(217,879)		(684,057)		(11,006,963)
Net Loss	(217,879)		(684,887)	$ (10,353,605)	$ (11,007,799)
Basic and diluted loss per share				$ (0.05)	$ (0.06)
Consolidated Statements of Cash Flow
Net loss from operating activities	$ (217,879)		(684,887)	$ (10,353,605)	$ (11,007,799)
Issuance of common stock for compensation					1,295,324
(Decrease) increase in due to related party				6,477,483	$ 6,477,483
Net cash used in operating activities			$ (1,275,484)	$ (3,263,340)		$ (715)

Corrections to Previously Iss26

Corrections to Previously Issued Consolidated Financial Statements (Details Textual) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016	Sep. 30, 2015
Corrections to Previously Issued Consolidated Financial Statements (Textual)
Collaborative agreement, description			Company discovered that there was a delay of accrual for the two payments in total of $10,000,000 as set forth in the Collaborative Agreement: 1) 3.5% of total payment related to the upfront payment shall be made upon the execution of the Collaborative Agreement; and 2) 6.5% of the total payment shall be made upon the first IND submission (which was submitted in March 2016).
Due to related party	$ 953,000		$ 953,000		$ 6,500,000
Total liabilities	1,056,130		1,056,130		6,556,470
Additional paid-in capital	10,746,464		10,746,464		4,733,461
Accumulated deficit	(12,008,288)		(12,008,288)		(11,323,401)
Total equity (deficit)	(1,048,077)		(1,048,077)		(6,379,118)
Selling, general and administrative expenses	169,427	$ 289,098	562,930	$ 349,486
Research and development expenses	17,500		67,848	10,000,000
Net loss from operations	(189,479)	(289,098)	(636,706)	(10,349,518)
Loss from continuing operations before income taxes	(217,879)	(292,401)	(684,057)	(10,352,769)
Net loss from operating activities	$ (217,879)	$ (293,237)	$ (684,887)	$ (10,353,605)
Basic and diluted loss per share	$ 0	$ 0	$ 0	$ (0.05)
Issuance of common stocks for compensation
(Decrease) increase in due to related party			$ (647,000)	6,477,483
Net cash used in operating activities			(1,275,484)	(3,263,340)
Net cash provided by financing activities			1,110,000	2,353,414
Co-development with related party	$ 90,000
Previously Reported on Form 10K [Member]
Corrections to Previously Issued Consolidated Financial Statements (Textual)
Due to related party
Total liabilities					56,470
Additional paid-in capital	10,586,464		10,586,464		4,733,401
Accumulated deficit	(11,848,288)	(669,207)	(11,848,288)	(669,207)	(4,823,401)
Total equity (deficit)					120,882
Selling, general and administrative expenses					4,497,263
Research and development expenses
Net loss from operations	(99,479)		(476,706)		(4,497,295)
Loss from continuing operations before income taxes	(217,879)		(524,057)		(4,506,963)
Net loss from operating activities	(217,879)		(524,887)	$ (353,605)	$ (4,507,799)
Basic and diluted loss per share					$ 0
Issuance of common stocks for compensation					$ 1,295,324
(Decrease) increase in due to related party				$ (22,517)	(22,517)
Net cash used in operating activities			(1,115,484)	(3,857,447)		$ (517)
Net cash provided by financing activities			950,000	2,947,521
Adjustments No.1 [Member]
Corrections to Previously Issued Consolidated Financial Statements (Textual)
Due to related party		6,500,000		6,500,000	6,500,000
Total liabilities					6,500,000
Additional paid-in capital	160,000		160,000
Accumulated deficit	(160,000)	(10,000,000)	(160,000)	(10,000,000)	(6,500,000)
Total equity (deficit)					(6,500,000)
Selling, general and administrative expenses					(3,500,060)
Research and development expenses			10,000,000		10,000,000
Net loss from operations	(90,000)		(160,000)		(6,499,940)
Loss from continuing operations before income taxes	(90,000)		(160,000)		(6,499,940)
Net loss from operating activities	(90,000)		(160,000)	$ (10,000,000)	$ (6,499,940)
Basic and diluted loss per share				$ (0.05)	$ (0.06)
Issuance of common stocks for compensation					$ (60)
(Decrease) increase in due to related party				$ 6,500,000	6,500,000
Net cash used in operating activities			(160,000)	594,107
Net cash provided by financing activities			160,000	(594,107)
Adjustments No.2 [Member]
Corrections to Previously Issued Consolidated Financial Statements (Textual)
Due to related party
Total liabilities
Additional paid-in capital					60
Accumulated deficit
Total equity (deficit)
Selling, general and administrative expenses					60
Research and development expenses
Net loss from operations					(60)
Loss from continuing operations before income taxes					(60)
Net loss from operating activities					$ (60)
Basic and diluted loss per share					$ 0
Issuance of common stocks for compensation					$ 60
(Decrease) increase in due to related party
Net cash used in operating activities						(198)
Restated [Member]
Corrections to Previously Issued Consolidated Financial Statements (Textual)
Due to related party		6,500,000		6,500,000	6,500,000
Total liabilities					6,556,470
Additional paid-in capital	10,746,464		10,746,464		4,733,461
Accumulated deficit	(12,008,288)	$ (10,669,207)	(12,008,288)	(10,669,207)	(11,323,401)
Total equity (deficit)					(6,379,118)
Selling, general and administrative expenses					997,263
Research and development expenses			10,000,000		10,000,000
Net loss from operations	(189,479)		(636,706)		(10,997,295)
Loss from continuing operations before income taxes	(217,879)		(684,057)		(11,006,963)
Net loss from operating activities	$ (217,879)		(684,887)	$ (10,353,605)	$ (11,007,799)
Basic and diluted loss per share				$ (0.05)	$ (0.06)
Issuance of common stocks for compensation					$ 1,295,324
(Decrease) increase in due to related party				$ 6,477,483	$ 6,477,483
Net cash used in operating activities			(1,275,484)	(3,263,340)		$ (715)
Net cash provided by financing activities			$ 1,110,000	$ (2,353,414)

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details) - USD ($)	Mar. 21, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Oct. 01, 2016	Sep. 30, 2016	Sep. 30, 2015
Summary of Significant Accounting Policies (Textual)
Forward split ratio	1 to 3.141
Common stock, par value		$ 0.001		$ 0.001			$ 0.001
Cash and cash equivalents amounted		$ 8,053	$ 84,904	$ 8,053	$ 84,904	$ 173,537	$ 173,537	$ 994,830
Common stock, share authorized		360,000,000		360,000,000			360,000,000
Income tax expense			$ 836	$ 830	$ 836

Going Concern (Details)

Going Concern (Details) - USD ($)	May 06, 2016	Feb. 28, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016
Going Concern (Textual)
Accumulated deficit			$ (12,008,288)		$ (12,008,288)		$ (11,323,401)
Net loss for the period			(217,879)	$ (293,237)	(684,887)	$ (10,353,605)
Negative cash flow					(165,484)	(909,926)
Accounts payable							$ 18,370
Collaborative Agreement [Member]
Going Concern (Textual)
Milestone payments to BioLite in cash	$ 2,600,000
Common stock newly issued, value	$ 900,000
Issuance of common shares, shares	562,500
Share price	$ 1.60
Percentage of payments under collaborative agreement					3.50%
Collaborative Agreement One [Member]
Going Concern (Textual)
Milestone payments to BioLite in cash		$ 650,000
Common stock newly issued, value		$ 5,850,000
Issuance of common shares, shares		2,925,000
Share price		$ 2
Accounts payable				$ 6,500,000		$ 6,500,000
Percentage of payments under collaborative agreement						6.50%

Collaborative Agreement (Detail

Collaborative Agreement (Details)	May 06, 2016USD ($)$ / sharesshares	May 26, 2017USD ($)Installments	Feb. 28, 2017USD ($)$ / sharesshares	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Sep. 30, 2016USD ($)	Aug. 26, 2016USD ($)	Dec. 29, 2015USD ($)
Collaborative Agreement (Textual)
Amount received from BioFirst Corporation				$ 953,000		$ 6,500,000
Accounts payable						$ 18,370
Collaborative Agreement [Member]
Collaborative Agreement (Textual)
Description of payment settlement schedule				● upfront payment shall upon the signing of this Collaborative Agreement: 3.5% of total payment. After receiving upfront payment from BriVision, BioLite has to deliver all data to BriVision in one week. ● upon the first IND submission, BriVision shall pay, but no later than December 15, 2016: 6.5% of total payment. After receiving second payment from BriVision, BioLite has to deliver IND package to BriVision in one week. ● at the completion of first phase II clinical trial, BriVision shall pay, but no later than September 15, 2017: 15% of total payment. After receiving third payment from BriVision, BioLite has to deliver phase II clinical study report to BriVision in three months. ● upon the phase III IND submission, BriVision shall pay, but no later than December 15, 2018: 20% of total payment. After receiving forth payment from BriVision, BioLite has to deliver IND package to BriVision in one week. ● at the completion of phase III, BriVision shall pay, but no later than September 15, 2019:25% of total payment. After receiving fifth payment from BriVision, BioLite has to deliver phase III clinical study report to BriVision in three months. ● upon the NDA submission, BriVision shall pay, but no later than December 15, 2020, BriVision shall pay: 30% of total payment. After receiving sixth payment from BriVision, BioLite has to deliver NDA package to BriVision in one week.
Amount received from BioFirst Corporation								$ 100,000,000
Upfront payments				$ 3,500,000
Milestone payments to BioLite in cash	$ 2,600,000
Common stock newly issued, value	$ 900,000
Common stock newly issued, shares | shares	562,500
Share price | $ / shares	$ 1.60
Percentage of payments under collaborative agreement				3.50%
Collaborative Agreement One [Member]
Collaborative Agreement (Textual)
Description of payment settlement schedule				Pursuant to the Collaborative Agreement, 6.5% of total payment, $6,500,000 shall be made upon the first IND submission which was submitted in March 2016. In February 2017, the Company remitted this amount to BioLite with $650,000 in cash and $5,850,000 in the form of newly issued shares of our common stock, at the price of $2.0 per share, for an aggregate number of 2,925,000 shares.
Amount received from BioFirst Corporation							$ 100,000,000
Milestone payments to BioLite in cash			$ 650,000
Common stock newly issued, value			$ 5,850,000
Common stock newly issued, shares | shares			2,925,000
Share price | $ / shares			$ 2
Licensing rights				$ 10,000,000
Accounts payable					$ 6,500,000
Percentage of payments under collaborative agreement					6.50%
Co-Dev Agreement [Member]
Collaborative Agreement (Textual)
Cash receivable from Rgene		$ 3,000,000
Number of installments | Installments		3
Proceeds from cash received		$ 90,000
Future net licensing income, percentage		50.00%

Related Parties Balances and 30

Related Parties Balances and Transactions (Details) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Related Party Transaction [Line Items]
Amount due to related party	$ 953,000	$ 6,500,000
BioLite, Inc. [Member]
Related Party Transaction [Line Items]
Amount due to related party		6,500,000
BioFirst Corporation [Member]
Related Party Transaction [Line Items]
Amount due to related party	950,000
YuanGene Corporation [Member]
Related Party Transaction [Line Items]
Amount due to related party	$ 3,000

Related Parties Balances and 31

Related Parties Balances and Transactions (Details 1) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Related Party Transaction [Line Items]
Unsecured borrowings from related parties	$ 953,000	$ 6,500,000
BioFirst Corporation [Member]
Related Party Transaction [Line Items]
Unsecured borrowings from related parties	950,000
YuanGene Corporation [Member]
Related Party Transaction [Line Items]
Unsecured borrowings from related parties	$ 3,000

Related Parties Balances and 32

Related Parties Balances and Transactions (Details Textual) - USD ($)	Jan. 26, 2017	May 26, 2017	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Sep. 30, 2016
Related Party Transaction [Line Items]
Amount received from BioFirst Corporation			$ 953,000			$ 953,000		$ 6,500,000
Interest expense			28,500		$ 3,753	47,500	$ 3,753
Accrued interest						$ 9,500		0
Payment to LionGene Corporation for consulting service				$ 70,000
Co-development agreement [Member]
Related Party Transaction [Line Items]
Description of payment settlement schedule		BriVision entered into a co-development agreement (the "Co-Dev Agreement") with Rgene (See Note 5). As of June 30, 2017, the Company has received an aggregate amount of $90,000 in cash. Since both Rgene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation, the Company has recorded the cash receipt of $90,000 in connection with the Co-Dev Agreement as additional paid-in capital during the nine months ended June 30, 2017.
Co-Dev Agreement [Member]
Related Party Transaction [Line Items]
Description of payment settlement schedule						The Company provided a one-time consulting service to LionGene Corporation for $70,000. Since both LionGene and the Company are related parties and under common control by a controlling beneficiary shareholder of YuanGene Corporation, the Company has recorded the full amount of $70,000 as additional paid-in capital during the nine months ended June 30, 2017.
BioFirst Corporation [Member]
Related Party Transaction [Line Items]
Amount received from BioFirst Corporation			$ 950,000			$ 950,000
BioFirst Corporation [Member] | Loan Agreement [Member]
Related Party Transaction [Line Items]
Amount received from BioFirst Corporation	$ 950,000
Loan bears interest terms	Loan bears interest at 1% per month (or equivalent to 12% per annum) and the Company is required to remit the interest payment monthly to the lender.
Loan maturity date	Feb. 1, 2018

Accrued Expenses and Other Pa33

Accrued Expenses and Other Payables (Details) - USD ($)	Jun. 30, 2017	Sep. 30, 2016
Accrued Expenses and Other Payables [Abstract]
Accruals for consulting fee	$ 31,640	$ 23,100
Accruals for audit fee	19,000	15,000
Accruals for interest expense	9,500
Accruals for rental expense	42,990
Total accrued expenses and other payables	$ 103,130	$ 38,100

Equity (Details)

Equity (Details) - USD ($)

Oct. 01, 2016

May 06, 2016

Mar. 21, 2016

Feb. 08, 2016

Feb. 28, 2017

Aug. 26, 2016

Feb. 17, 2016

Jun. 30, 2017

Jun. 30, 2016

Jun. 30, 2017

Jun. 30, 2016

Sep. 30, 2016

Dec. 29, 2015

Oct. 30, 2015

Equity (Textual)

Common stock, authorized

360,000,000

360,000,000

360,000,000

Common stock, par value

$ 0.001

$ 0.001

$ 0.001

Description of forward split

1 to 3.141

Subscription receivable

$ 350,000

Payment of American BriVision

$ 953,000

$ 953,000

$ 6,500,000

Consulting agreement, description

The Company entered into a Consulting Agreement with Kazunori Kameyama ("Kameyama") for the provision of services related to the clinical trials and other administrative work, public relation work, capital raising, trip coordination, In consideration for providing such services, the Company agreed to indemnify the consultant in an amount of $150 per hour in cash up to $3,000 per month, and issue to Kameyama the Company's common stock at $1.00 per share for any amount exceeding $3,000. The Company's stocks will be calculated and issued in December every year. The contract will be terminated on September 30, 2017. For the nine months ended on June 30, 2017, the Company recognized (as appropriate relative to the periods and manner that the Company would recognize cash payments under the same arrangement) the cost of the appropriate number of the 1,688 shares at the current fair value as of December 31, 2016 and June 30, 2017.

Stock-based compensation

$ 2,552

$ 5,928

2016 Plan [Member]

Equity (Textual)

Common stock issued pre-stock split

50,000

Common stock issued post-stock split

157,050

BioLite, Inc. [Member]

Equity (Textual)

Common stock, par value

$ 0.001

Issuance of common shares

$ 1,468,750

Purchase price per share

$ 1.60

Net proceeds from offering

$ 2,350,000

Share Exchange Agreement [Member]

Equity (Textual)

Common stock issued pre-stock split

52,336,000

Common stock issued post-stock split

164,387,376

Share Exchange Agreement 2 [Member]

Equity (Textual)

Common stock issued pre-stock split

51,945,225

Common stock issued post-stock split

163,159,952

Percentage of common shares issued and outstanding

79.70%

Percentage of issued share capital

100.00%

Share Exchange Agreement 3 [Member]

Equity (Textual)

Common stock issued pre-stock split

52,936,583

Common stock issued post-stock split

166,273,921

Exchange ratio

0.2536-for-1

Share Exchange Agreement 4 [Member]

Equity (Textual)

Common stock issued pre-stock split

65,431,144

Common stock issued post-stock split

205,519,223

Collaborative Arrangement [Member]

Equity (Textual)

Issuance of common shares

$ 900,000

Issuance of common shares, shares

562,500

Share price

$ 1.60

Payment of American BriVision

$ 100,000,000

Percentage of payments under collaborative agreement

3.50%

Collaborative Arrangement One [Member]

Equity (Textual)

Issuance of common shares

$ 5,850,000

Issuance of common shares, shares

2,925,000

Share price

$ 2

Payment of American BriVision

$ 100,000,000

Percentage of payments under collaborative agreement

6.50%

Total payment upon first IND submission

$ 6,500,000

$ 6,500,000

Remitted amount

$ 650,000

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Numerator:
Net loss	$ (217,879)	$ (293,237)	$ (684,887)	$ (10,353,605)
Weighted-average shares outstanding:
Weighted-average shares outstanding - Basic & Diluted	213,746,647	208,779,424	212,203,790	208,779,424
Earnings per share
-Basic & Diluted	$ 0	$ 0	$ 0	$ (0.05)

Commitments and Contingencies36

Commitments and Contingencies (Details)	Jun. 30, 2017USD ($)
Commitments and Contingencies [Abstract]
Year ending September 30, 2017	$ 14,802
Total	$ 14,802

Commitments and Contingencies37

Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Commitments and Contingencies (Textual)
Rental expense	$ 23,640	$ 7,727	$ 56,380	$ 20,291

Subsequent Event (Details)

Subsequent Event (Details)	1 Months Ended
	Jul. 24, 2017USD ($)Installments	Jun. 30, 2017USD ($)	Sep. 30, 2016USD ($)
Subsequent Event [Line Items]
Total payments in cash or stock		$ 953,000	$ 6,500,000
Collaborative Agreement [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Total payments in cash or stock	$ 3,000,000
Number of installments | Installments	2
Date of total payment through cash or stock	Sep. 30, 2018
Upfront payments	$ 300,000
Percentage of payments under collaborative agreement	10.00%
Percentage of future net licensing income	50.00%